Concomitant Left Atrial Appendage Occlusion and Transcatheter Aortic Valve Replacement Among Patients With Atrial Fibrillation
Circulation · 05.03.2024 · 149 (10) · 734-743
DOI: 10.1161/circulationaha.123.067312 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Circulation, erschienen am 05.03.2024. Verfasst von Samir R Kapadia und 18 weiteren Autor:innen. Beteiligte Einrichtung: Cleveland Clinic, Cleveland, OH (S.R.K., A.K., V.M., K.W., Q.W.). Hauptthemen laut MEDLINE: Atrial Fibrillation, Transcatheter Aortic Valve Replacement, Atrial Appendage, Stroke. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Boston Scientific Corporation.
Abstract (Originalsprache)
BACKGROUND: Atrial fibrillation (AF) is common in patients undergoing transcatheter aortic valve replacement (TAVR) and is associated with increased risk of bleeding and stroke. While left atrial appendage occlusion (LAAO) is approved as an alternative to anticoagulants for stroke prevention in patients with AF, placement of these devices in patients with severe aortic stenosis, or when performed at the same time as TAVR, has not been extensively studied. METHODS: WATCH-TAVR (WATCHMAN for Patients with AF Undergoing TAVR) was a multicenter, randomized trial evaluating the safety and effectiveness of concomitant TAVR and LAAO with WATCHMAN in AF patients. Patients were randomized 1:1 to TAVR + LAAO or TAVR + medical therapy. WATCHMAN patients received anticoagulation for 45 days followed by dual antiplatelet therapy until 6 months. Anticoagulation was per treating physician preference for patients randomized to TAVR + medical therapy. The primary noninferiority end point was all-cause mortality, stroke, and major bleeding at 2 years between the 2 strategies. RESULTS: The study enrolled 349 patients (177 TAVR + LAAO and 172 TAVR + medical therapy) between December 2017 and November 2020 at 34 US centers. The mean age of patients was 81 years, and the mean scores for CHA 2 DS 2 -VASc and HAS-BLED (Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile INR, Elderly, Drugs/alcohol concomitantly) were 4.9 and 3.0, respectively. At baseline, 85.4% of patients were taking anticoagulants and 71.3% patients were on antiplatelet therapy. The cohorts were well-balanced for baseline characteristics. The incremental LAAO procedure time was 38 minutes, and the median contrast volume used for combined procedures was 119 mL versus 70 mL with TAVR alone. At the 24-month follow-up, 82.5% compared with 50.8% of patients were on any antiplatelet therapy, and 13.9% compared with 66.7% of patients were on any anticoagulation therapy in TAVR + LAAO compared with TAVR + medical therapy group, respectively. For the composite primary end point, TAVR + LAAO was noninferior to TAVR + medical therapy (22.7 versus 27.3 events per 100 patient-years for TAVR + LAAO and TAVR + medical therapy, respectively; hazard ratio, 0.86 [95% CI, 0.60–1.22]; P noninferiority
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cleveland Clinic, Cleveland, OH (S.R.K., A.K., V.M., K.W., Q.W.).
- Intermountain Medical Center, Salt Lake City, UT (B.W.).
- Baylor Scott and White The Heart Hospital, Plano, TX (S.P.).
- University of Buffalo, NY (V.I.).
- Santa Barbara Cottage Hospital, CA (J.A.).
- Banner University Medical Center, Phoenix, AZ (P.G.).
ORCID-Profile: Samir R Kapadia, Amar Krishnaswamy, Brian Whisenant, Philip Gideon, Carlos Sanchez, Torsten Vahl, Venu Menon, Kathy Wolski
Förderung
- Boston Scientific Corporation
Zitieren
APA
Kapadia, S. R., Krishnaswamy, A., Whisenant, B., Potluri, S., Iyer, V., Aragon, J., Gideon, P., Strote, J., Leonardi, R., Agarwal, H., Larrain, G., Sanchez, C., Panaich, S. S., Harvey, J., Vahl, T., Menon, V., Wolski, K., Wang, Q., & Leon, M. B. (2024). Concomitant Left Atrial Appendage Occlusion and Transcatheter Aortic Valve Replacement Among Patients With Atrial Fibrillation. Circulation, 149(10), 734-743. https://doi.org/10.1161/circulationaha.123.067312
Vancouver
Kapadia SR, Krishnaswamy A, Whisenant B, Potluri S, Iyer V, Aragon J, et al. Concomitant Left Atrial Appendage Occlusion and Transcatheter Aortic Valve Replacement Among Patients With Atrial Fibrillation. Circulation. 2024;149(10):734-743. doi:10.1161/circulationaha.123.067312
BibTeX
@article{Kapadia2024,
author = {Kapadia, Samir R and Krishnaswamy, Amar and Whisenant, Brian and Potluri, Srinivasa and Iyer, Vijay and Aragon, Joseph and Gideon, Philip and Strote, Justin and Leonardi, Robert and Agarwal, Himanshu and Larrain, German and Sanchez, Carlos and Panaich, Sidakpal S and Harvey, James and Vahl, Torsten and Menon, Venu and Wolski, Kathy and Wang, Qiuqing and Leon, Martin B},
title = {Concomitant Left Atrial Appendage Occlusion and Transcatheter Aortic Valve Replacement Among Patients With Atrial Fibrillation},
journal = {Circulation},
year = {2024},
volume = {149},
number = {10},
pages = {734--743},
doi = {10.1161/circulationaha.123.067312}
}
EUVIMED